Contact Us
CKD OTTO PHARMA
Better Life Through
Better Medicine
View Products
CKD OTTO PHARMA
SPECIALIZED IN
ONCOLOGY PRODUCT
View Products
About Us

Our Journey in Cancer Pharmacy

CKD OTTO Pharma is a joint venture company between Chong Kun Dang Pharm, a leading Pharmaceutical company in Korea, and Otto Pharmaceutical Industries, a part of Indonesian leading pharmaceutical company, MENSA Group.

We are the first oncology manufacturer that obtain Halal certificate in Indonesia with excellent category in February 2019 from MUI (Indonesian Council of Ulama). Prior to this certificate, we have received GMP (Good Manufacturing Practice) certificate from BPOM (Indonesian FDA) in September 2018.

Certificates

Certified Quality Assurance

Our Product

Trusted Choices in Oncology Treatment

Our Advantages

Why Choose Us?

We at CKD OTTO Pharma are not only committed to innovation in cancer treatment, but also to safety and quality.

GMP certified, our production site is also set for EMA (European Medicines Agency) and SFDA (Saudi Food and Drug Authority).
CKD OTTO Pharma and Export Country

Our Global Footprint

Across continents and diverse cultures, our global footprints are shown our dedication to reaching every corner of the world. We have qualified field forces and distributor networks that cover across nation.

Our extensive global partner has enabled us to provide our products across MENA, GCC and Asia countries.

MENA
GCC
ASEAN
East Asia
Oncology Insights

Watch Our Innovation

dca79a1122f7056372d0426f3204fd80
Group 75(1)
News

Information on CKD OTTO Pharma

CSR Activities
Indonesian Ministry of Health Sends 3 Tons of Medicine and Health Device to Sri Lanka

Jakarta, 28 April 2022 Sri Lanka kini tengah mengalami krisis yang berdampak pada kelangkaan obat dan alat kesehatan. Sebagai respons atas situasi tersebut, Pemerintah Indonesia …

Read More
Press Releases
Chong Kun Dang’s Indonesian unit signs $32-million export deal with Algerian state firm
Chong Kun Dang said its Indonesian joint venture ...
Read More
Press Releases
RI-South Korea Joint Venture Establishes $30 Million Oncology Factory
RI-South Korea joint venture establishes $30 million oncology ...
Read More
Corporate News
RI-South Korea Joint Venture Establishes $30 Million Oncology Factory
RI-South Korea joint venture establishes $30 million oncology ...
Read More
Scroll to Top